Table 4.
Stratified results of quantification of NET formation assay.
| NET production (AFU), median (IQR) | |||
|---|---|---|---|
| Stimulant | Healthy control (n = 20) |
Colorectal cancer (n = 45) |
p value |
|
| |||
| Unstimulated | 9735 (6429–11840) | 11347 (4927–8341) | 0.0209 |
| PMA | 42173 (35243–52315) | 39238 (29497–47988) | 0.2353 |
| IL-8 | 8644 (6098–12304) | 11915 (9031–15358) | 0.0032 |
| LPS | 10576 (7366–12946) | 12473 (9381–16542) | 0.0428 |
| fMLP | 9566 (8345–11973) | 12194 (8602–15991) | 0.0868 |
|
| |||
| Stimulant | Rectal cancer (n = 18) |
Colonic cancer (n = 27) |
p value |
|
| |||
| Unstimulated | 10190 (8057–14580) | 12140 (9980–1499) | 0.2711 |
| PMA | 39490 (29050–49190) | 38100 (29370–48840) | 0.8078 |
| IL-8 | 11080 (8245–15610) | 11960 (9998–15350) | 0.4655 |
| LPS | 11600 (8515–15580) | 12730 (11210–18640) | 0.2813 |
| fMLP | 10520 (8384–14910) | 12440 (9203–16850) | 0.4241 |
|
| |||
| Stimulant | Early stage (Dukes' A/B) (n = 32) |
Late stage (Dukes' C/D) (n = 13) |
p value |
|
| |||
| Unstimulated | 11340 (8862–14880) | 11350 (7476–15150) | 0.7353 |
| PMA | 39490 (29640–47200) | 38100 (27730–48530) | 0.8314 |
| IL-8 | 11990 (9574–15750) | 10320 (7790–14820) | 0.3105 |
| LPS | 12600 (9783–16280) | 11540 (9106–17270) | 0.6795 |
| fMLP | 12200 (8500–16050) | 11780 (8624–14840) | 0.6432 |
|
| |||
| Stimulant | Neoadjuvant therapy (n = 11) |
Straight to surgery (n = 34) |
p value |
|
| |||
| Unstimulated | 9039 (7507–13230) | 11780 (9031–15460) | 0.1577 |
| PMA | 34830 (27140–41590) | 40330 (29560–49070) | 0.2002 |
| IL-8 | 10320 (8306–15190) | 12010 (9349–15980) | 0.2295 |
| LPS | 13900 (8323–14930) | 12380 (10070–17120) | 0.4516 |
| fMLP | 11400 (8339–15870) | 12330 (8704–17200) | 0.4205 |
|
| |||
| Stimulant | Clavien-Dindo < 3 (n = 38) |
Clavien-Dindo ≥ 3 (n = 6) |
p value |
|
| |||
| Unstimulated | 11090 (8240–14670) | 14780 (12630–18330) | 0.0639 |
| PMA | 38100 (29620–47760) | 40330 (27690–60140) | 0.6522 |
| IL-8 | 11820 (8517–14300) | 15840 (11300–19070) | 0.0796 |
| LPS | 12290 (8858–15750) | 15180 (11620–19710) | 0.2359 |
| fMLP | 11760 (8339–14510) | 18340 (12330–22400) | 0.0242 |
|
| |||
| Stimulant | LOS ≤ 5 days (n = 15) |
LOS > 5 days (n = 29) |
p value |
|
| |||
| Unstimulated | 11090 (7507–14200) | 12140 (8879–15260) | 0.3220 |
| PMA | 36430 (27510–43650) | 39740 (29500–50280) | 0.2760 |
| IL-8 | 11840 (7935–14200) | 12250 (9261–6443) | 0.4576 |
| LPS | 9408 (6915–15170) | 13180 (11250–17270) | 0.1812 |
| fMLP | 9008 (7599–13290) | 12530 (10690–17940) | 0.0476 |
|
| |||
| Stimulant | Survived (n = 40) |
Died (n = 5) |
p value |
|
| |||
| Unstimulated | 11180 (8301–14640) | 14760 (10340–18880) | 0.2707 |
| PMA | 38670 (29640–45400) | 50810 (25310–74680) | 0.3033 |
| IL-8 | 11830 (9004–14970) | 15370 (10960–20510) | 0.1644 |
| LPS | 12290 (8982–16280) | 13900 (12360–20780) | 0.2405 |
| fMLP | 11680 (8354–14530) | 16110 (12310–23420 | 0.0533 |